Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=-funder_divisions
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-funder_divisions", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1419&sort=-funder_divisions", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-funder_divisions", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=-funder_divisions" }, "data": [ { "type": "Grant", "id": "8838", "attributes": { "award_id": "1U01GH002346-01", "title": "GH21-003, Advancing Public Health Research in Kenya", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2021-09-30", "end_date": "2026-09-29", "award_amount": 6329348, "principal_investigator": { "id": 24649, "first_name": "M KARIUKI", "last_name": "NJENGA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 306, "ror": "https://ror.org/05dk0ce17", "name": "Washington State University", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 306, "ror": "https://ror.org/05dk0ce17", "name": "Washington State University", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "(ADMINISTRATIVE CORE) Our Consortium consisting of Washington State University (WSU), the Liverpool School of Tropical Medicine (LSTM), and the Kenya Medical Research Institute (KEMRI) proposes to support KEMRI to develop and manage a highly cost-effective and sustainable KEMRI/CGHR Research Platform (KRP) in western Kenya (under “Category 1. Research Coordination and Administration” of the administrative core). The platform includes the population-based health and demographic surveillance systems, laboratories in Kisumu and Nairobi, clinical research centers in Kisumu, and offices and shared services at the Kisian campus, Kisumu. Between 2014 and 2020, KRP’s day-to-day management was changed three times to make it more efficient, transparent, affordable, and less contentious with KEMRI, CDC, and other partners. Currently, the platform is managed by KEMRI, with CDC (through its partners) contributing financially together with the other international partners who share the platform. WSU and LSTM have an excellent relationship with KEMRI and its partners and many years of administrative and technical expertise in Kenya. Following extensive discussions and agreements leading up to this joint application, WSU, LSTM, and KEMRI central leadership will support KEMRI/CGHR to implement a management plan to strengthen the Center’s capacity to assume cost-effective and sustainable management of the platform in support of their public health research in Kenya. This will include a phased introduction of financial and administrative management systems, mutually agreed systems for cost-sharing across all national and international partners sharing the facilities, close fiscal oversight by WSU, and mentorship and training. KEMRI has already taken critical steps to streamline the platform’s management and strengthen its leadership, including the appointment of three senior staff at KEMRI/CGHR, the revision of policies to enhance decision-making at the Center level, and commitment to providing its share of financial support. It also includes the rolling out of an electronic system for the management of grant and ethics applications. As part of “Category 2. Research Laboratory Administration”, we will maintain accreditation standards, quality assurance processes, and integrated biosafety and biosecurity systems to support KEMRI state-of-the-art laboratories. We will also introduce a laboratory information management system, including for effective management of samples and associated data. The KEMRI laboratories recently demonstrated their utility to the country by providing >70% of the country’s testing capacity for COVID-19 pandemic. In addition, we present evident technical expertise to lead the Research Core areas identified in the RFA, including HIV and TB, malaria, influenza, and other respiratory pathogens, zoonotic diseases, antimicrobial resistance, neglected tropical diseases, non-communicable diseases, and vaccine- preventable diseases. Experienced WSU and LSTM scientists will team up with KEMRI and CDC counterparts to design, implement, and publish research, an approach designed to train and mentor KEMRI scientists in applying and managing research funding. In the accompanying Research Core proposals, these teams describe field and laboratory activities that address each required outcome and objective of the RFA. Table 5 of this Administrative Core provides a work plan showing how each study will be implemented over the program’s 5-year duration.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8840", "attributes": { "award_id": "1U18FD007490-01", "title": "Mississippi Perinatal COVID-19 Registry", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24651, "first_name": "Carrie", "last_name": "Bryant", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2023-08-31", "award_amount": 2000000, "principal_investigator": { "id": 24652, "first_name": "Norma Beatriz", "last_name": "Ojeda", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1506, "ror": "", "name": "UNIVERSITY OF MISSISSIPPI MED CTR", "address": "", "city": "", "state": "MS", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1506, "ror": "", "name": "UNIVERSITY OF MISSISSIPPI MED CTR", "address": "", "city": "", "state": "MS", "zip": "", "country": "United States", "approved": true }, "abstract": "Perinatal COVID-19 Databank Project Summary The COVID-19 pandemic affected mostly adult population over 60 years of age during the first months of its inception around the world. However, due to the rapid spread of the virus in the community children and pregnant women were affected within the first year of the pandemic. The effect of COVID-19 in children was reported in over two thousand articles since the beginning of the pandemic. The majority of these articles focused on the clinical feature of acute COVID-19 onset in the pediatric population. Moreover, reports of COVID-19 cases in children are growing steadily since March 2020 according to the CDC’s Morbidity and Mortality Weekly Report on 6/ 2021. The perinatal exposure to SARS CoV-2 in infants from mothers diagnosed with COVID-19 is a topic characterized by controversy and lack of clear understanding on the etiology of the condition, and the short and long term consequences. Therefore, the best approach to understand the etiology, management and consequences of COVID-19 is to study its natural progression. Birth cohort studies provide critical information for the investigation of the origins, and natural progression of diseases. This project proposes the development of a shareable compendium of perinatal COVID-19 cases from the State of Mississippi. The Patient Cohort Explorer and COVID-19 Research Registry databases developed at the University of Mississippi Medical Center will serve as the foundation to build a compendium of perinatal COVID-19 cases including mother/infant dyads. This database will capture clinical and demographic information from mother and newborns infant affected by COVID-19, and receiving medical care in the University of Mississippi Medical Center, which is the only referral center for maternal fetal healthcare in the State. In addition, the database will include information from satellite clinics associated with the Medical Center, and COVID-19 data from public health datasets from the Mississippi State Department of Health. This database will provide shareable de-identified patient information with query, pairing and follow-ups capabilities on medical conditions, diagnosis, management, treatment and outcomes. In addition, this project will incorporate and link data from the University of Mississippi Medical Center biobank management system and the geographic information system providing access to biological samples and geolocation of COVID-19 cases.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8843", "attributes": { "award_id": "1R01FD007457-01", "title": "Manufacturing and Characterization of Potent mRNA Lipid Nanoparticle Vaccines at Multiple Scales", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24621, "first_name": "Manuel", "last_name": "Osorio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2024-08-31", "award_amount": 498998, "principal_investigator": { "id": 24654, "first_name": "MIKELL", "last_name": "PAIGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 239, "ror": "https://ror.org/02jqj7156", "name": "George Mason University", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 239, "ror": "https://ror.org/02jqj7156", "name": "George Mason University", "address": "", "city": "", "state": "VA", "zip": "", "country": "United States", "approved": true }, "abstract": "mRNA vaccines have received emergency authorization approval for Covid-19 and are under development for several other infectious diseases. The mRNA-encoded immunogen in these vaccines is delivered inside a lipid nanoparticle (LNP) that comprises four lipids, the most important being the ionizable lipid that is responsible for releasing the mRNA from intracellular endosomes through protonation of amine groups that interact with the endosomal membrane. Clinical studies showed these vaccines are highly efficacious with over 94% of patients protected from SARS-CoV-2 infection. Although the successful development of mRNA LNP vaccines for SARS- Cov-2 constitutes a major breakthrough for a novel medical modality, it has also highlighted several unanswered questions surrounding this platform that require urgent investigation including : 1) What are the critical features of mRNA LNP manufacturing that need to be respected to create potent systems ? 2) What is functional consequence of truncated mRNA transcripts produced by in vitro translation (IVT) or by degradation and how can they be minimized through IVT optimization ? 3) What causes degradation of mRNA LNPs during manufacturing and storage and how can this be measured and minimized ? We recently discovered a new process to rationally design ionizable lipids for increased potency. We also discovered a novel manufacturing process to assemble the mRNA LNP such that the same lipid and mRNA components produce a much more efficient and potent delivery system. This allows more of the mRNA in the LNP to be translated thereby reducing dose and reactogenicity and increasing the number of people that can be vaccinated with the same quantity of vaccine. We have initiated studies to characterize and understand mRNA LNP stability that can affect the quality and performance of these vaccines. In this proposal we will perform studies to further the understanding of how mRNA LNPs are assembled and manufactured at different manufacturing scales from laboratory scale to commercial scale. The lack of public information in this area is a major impediment to improving and broadening the use of this new vaccine modality. We will also illuminate the presence and importance of the heterogeneity of different transcripts in the mRNA drug substance and how that heterogeneity could impact product performance. And finally, the stability of mRNA LNPs during manufacturing and storage will be studied to understand the degradation mechanisms causing loss of bioactivity and structural integrity of the mRNA and lipids, how to measure these properties, and develop formulations that have extended stability profiles compared to current products.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8849", "attributes": { "award_id": "1U18FD007509-01", "title": "Developing and validating serological assays to SARS-COV-2 for highly susceptible animal species", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24456, "first_name": "Olgica", "last_name": "Ceric", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-15", "end_date": "2023-08-31", "award_amount": 225000, "principal_investigator": { "id": 24661, "first_name": "Roman", "last_name": "Pogranichniy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 197, "ror": "https://ror.org/05p1j8758", "name": "Kansas State University", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 197, "ror": "https://ror.org/05p1j8758", "name": "Kansas State University", "address": "", "city": "", "state": "KS", "zip": "", "country": "United States", "approved": true }, "abstract": "SARS-CoV-2 is an enveloped, positive-sense RNA virus that is known to interact with the angiotensin- converting enzyme-2 (ACE2) receptor of several species, including humans, cats, dogs, minks, ferrets, deer, and others. Since its emergence in Wuhan, China in late 2019, SARS-CoV-2, the causative agent of COVID- 19, has been classified as a pandemic, causing havoc on public health and resulting in worldwide lockdowns. Due to its sudden emergence, as well as its similarity to SARS-CoV-1 and MERS-CoV, it is suspected that SARS-CoV-2 likely had an intermediate animal host. However, the similarities in the ACE2 receptors of coronaviruses have sparked the question of which animal species are susceptible to SARS-CoV-2, and capable of viral transmission. Reverse-zoonosis has been described in a few of these species, indicating that human-animal interactions can pose two-sided risks for SARS-CoV-2 infection. Therefore, it is critical to produce accurate diagnostic serological tests for animals to understand prevalence of the virus in the animal population. This project will compare diagnostic results between commercial ELISAs, developed in-house ELISAs, and serum neutralization assays for SARS-CoV-2, as well as Western blot against other coronaviruses to rule out cross-reactivity. The outcome of this study will provide insight into the accuracy (Se/Sp) of commercially available serological tests, newly developed in-house serological techniques, and collect data on SARS-CoV-2 prevalence in target species, which will include minks, ferrets, white-tailed deer, domestic dogs and cats, cows, sheep, and goats.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8850", "attributes": { "award_id": "1R01OH012045-01A1", "title": "Resolving Occupational Exposure-Induced Lung Disease", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24462, "first_name": "BRIDGETTE E", "last_name": "GARRETT", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2025-08-31", "award_amount": 545912, "principal_investigator": { "id": 24662, "first_name": "Jill A", "last_name": "Poole", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 628, "ror": "https://ror.org/00thqtb16", "name": "University of Nebraska Medical Center", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 628, "ror": "https://ror.org/00thqtb16", "name": "University of Nebraska Medical Center", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true }, "abstract": "Occupational lung diseases are the primary cause of occupation-associated illness in the U.S. based on frequency, severity, and preventability of the illnesses. Most occupational lung diseases are caused by repeated, long-term exposure to hazardous agents, but even a severe single exposure can damage the lungs. There are currently no medical therapies available to ameliorate lung injury/inflammation without exerting untoward side effects. The inability to adequately treat workers following occupational inflammatory exposure leads to chronic disease, and workers with respiratory disease have a higher incidence of filing for disability compared to those without respiratory disease. Importantly, there is a re-emergence in traditional respiratory occupational hazards caused by bacteria biological agents such as endotoxin. Exposures to endotoxin are high in agricultural production and emerging sectors such as waste treatment, recycling, biotech food production and processing industries. The COVID19 pandemic rapidly transpired as a devastating occupational respiratory viral-induced health illness significantly impacting workers of food processing plants with limited efficacious therapies. Without guidelines or therapies for the management of occupational exposure-induced lung injury/inflammation, there is an urgent and unmet need to identify alternative approaches to reduce disease burden. Our long-term goal is to find new strategies to promote the resolution of occupational exposure-associated lung inflammatory disease before it progresses to irreversible lung disease. Our recent discoveries using single cell RNA sequencing coupled with flow cytometry strongly implicate the recruited monocyte/macrophage, and we uncovered that delivering amphiregulin and interleukin (IL)-10 as lung-directed therapies appear to beneficially effect lung recovery processes post-occupational exposures. Our central hypothesis is that targeted cellular and mediator interventional approaches following various occupational inflammatory inhalant exposures can be developed to hasten lung recovery to reduce disease development. To model occupational bacterial and viral component- induced lung inflammation, Toll-like receptor (TLR) agonists and agriculture organic dust extract will be utilized. We seek to test our hypothesis by addressing three independent and synergistic aims. In Aim 1, we will determine the time-dependent cellular and specific monocyte/macrophage lung cell events following occupational exposures and whether targeting these cells hastens lung recovery. In Aim 2, we will determine the role of amphiregulin as a potential lung-directed therapeutic approach in the resolution inhalant occupational exposures. In Aim 3, we will determine how inhalant IL-10 treatment works to promote repair in the recovery process after lung inflammation induced by occupational exposures. The results of these studies will have an important positive impact because they lay the pre-clinical groundwork for understanding key cellular and mediator responses, and the ultimate development of new strategies to treat occupational exposure-induced lung inflammation prior to the development of irreversible lung disease.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8854", "attributes": { "award_id": "1R01HS027804-01A1", "title": "TELE-TOC: Telehealth Education Leveraging Electronic Transitions Of Care for COPD Patients - Resubmission - 1", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 23886, "first_name": "Derrick", "last_name": "Wyatt", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-10", "end_date": "2026-08-31", "award_amount": 400000, "principal_investigator": { "id": 24667, "first_name": "Joanna", "last_name": "Abraham", "orcid": null, "emails": "[email protected]", "private_emails": null, "keywords": "[]", "approved": true, "websites": "[]", "desired_collaboration": "", "comments": "", "affiliations": [ { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 24668, "first_name": "Vineet", "last_name": "Arora", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 24669, "first_name": "Valerie G", "last_name": "Press", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 289, "ror": "https://ror.org/024mw5h28", "name": "University of Chicago", "address": "", "city": "", "state": "IL", "zip": "", "country": "United States", "approved": true }, "abstract": "Transitions of Care (TOC) for high-risk, frequently hospitalized adults with chronic diseases are complex, costly, and vulnerable to safety threats and poor health outcomes. Communication breakdowns, information lapses, and IT-induced unintended consequences can result in poor follow-up and medication non-adherence, both of which contribute to preventable readmissions or emergency room (ER) visits. The Transitional Care Model (TCM) aims to reduce such risks through a holistic, collaborative, patient-centered approach with in-home interventions. Prior to the SARS-CoV-2 pandemic and resulting coronavirus disease 2019 (COVID-19), most in- home interventions relied on in-person visits, which can be cost-prohibitive and unsustainable. One potential sustainable and scalable solution is to use telehealth for in-home virtual visits; however, use of telehealth for post-discharge TOC interventions has not been routinely implemented. In the post-COVID-19 era, given the rapid expansion of telehealth, hospitals are well-positioned to initiate this virtual care. In-home virtual visits may be particularly promising for patients with chronic obstructive pulmonary disease (COPD), who are often hospitalized, have multiple comorbidities, and require intensive medication teaching due to rampant inhaler misuse. COPD affects more than 16 million US adults, many of whom are older, contribute ~$50 billion to healthcare costs annually, experience high rates of acute care revisits, often due to care coordination failures. For this reason, Medicare’s Hospital Readmission Reduction Program (HRRP) aims to incentivize hospitals to implement TOC programs for increased quality and value of care for COPD patients. However, currently, such programs fall short of aligning with the full TCM. In-home interventions may be particularly salient for improving medication skills and outcomes for patients with COPD given rampant inhaler misuses, the effectiveness of in- hospital inhaler education, and evidence showing the need for inhaler education reinforcement post discharge. Thus, our trans-disciplinary team proposes to implement and evaluate “TELE-TOC: Telehealth Education: Leveraging Electronic Transitions Of Care for COPD patients,” which seeks to integrate virtual, pharmacy-based, in-home visits for COPD patients within our hospital’s existing COPD HRRP. Our central hypotheses are that virtual visits with pharmacists will be feasible to implement and will result in improved medication use and outcomes among COPD patients at high risk for readmission. We aim to iteratively design TELE-TOC using participatory study design and stakeholder input. We will then test the effectiveness of adding TELE-TOC virtual visits in a randomized controlled trial among COPD patients enrolled in our HRRP program. Lastly, we will develop a plan for a dissemination strategy and roadmap with national stakeholders to facilitate widescale adoption of TELE-TOC nationwide.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8855", "attributes": { "award_id": "1R01HS028669-01", "title": "Characterizing the ImPact of COVID-19 on Antibiotic PreScribing in AcutE Care and IDentifying Resilient Stewardship Strategies (POISED)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24670, "first_name": "Leyi", "last_name": "Lin", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2026-08-31", "award_amount": 499999, "principal_investigator": { "id": 24671, "first_name": "Michael Santino", "last_name": "Pulia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in over 26 million infections and overwhelmed healthcare systems throughout the U.S. The novel nature of COVID-19 has generated unprecedented diagnostic and therapeutic dilemmas. One area of emerging concern is the collateral impact of the pandemic on increased antibiotic prescribing and an associated acceleration of bacterial resistance. For instance, early reports indicate that a high percentage of patients hospitalized with COVID-19 receive antibiotics despite few having confirmed bacterial co-infections. In addition to the public health implications, overuse of antibiotics is also a threat to patient safety due to the risk of serious adverse drug events and Clostridioides difficile colitis. In January 2021, the Society for Healthcare Epidemiology of America issued a white paper outlining research priorities related to COVID-19 that highlighted an urgent need to “identify the impact of changes in health care utilization and delivery on antibiotic prescribing” and “develop and implement optimal Antimicrobial Stewardship Program (ASP) strategies to improve antimicrobial use and patient outcomes while adapting to changing healthcare delivery during COVID-19”. This project is specifically designed to address this call to action as we aim to comprehensively characterize the impact of the COVID-19 pandemic on antibiotic prescribing and bacterial resistance trends in acute care hospitals and identify strategies that effectively promote resilient antibiotic stewardship. The assembled team is uniquely qualified to conduct this project given our expertise in evaluating antibiotic prescribing patterns, access to data from ~350 U.S. hospitals and extensive experience using systems engineering methods to analyze stewardship interventions. For the quantitative analyses, we will first characterize overall and condition specific antibiotic prescribing trends before and after COVID-19 using an interrupted time series analysis. Next, we will identify patient and hospital level factors that increased the risk of non-indicated antibiotic prescribing during the COVID-19 pandemic, with the goal of identifying potential intervention targets. Finally, we will complete a systems engineering guided qualitative analysis, focused on hospitals that least and most effectively mitigated the impact of COVID-19 on antibiotic prescribing, to identify systems-level contextual factors and strategies. These results will be used in a multidisciplinary co-design process to develop an antibiotic stewardship implementation toolkit that enhances resiliency during operational upheaval and is transferable between organizations. Given the dynamic nature of the pandemic (e.g. variant strains), it is imperative to classify the previous, ongoing and future adverse impacts on antibiotic prescribing to guide development of tailored stewardship strategies for widespread dissemination. This work represents a vital contribution to AHRQ’s ongoing efforts to combat both COVID-19 and the longstanding pandemic of antimicrobial-resistant infections.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8856", "attributes": { "award_id": "1R21OH012201-01", "title": "Moral Injury Among Healthcare Workers on the Frontlines of the COVID-19 Crisis: Developing a Blueprint for Awareness, Prevention, and Mitigation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24486, "first_name": "Maria", "last_name": "Lioce", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2023-08-31", "award_amount": 196396, "principal_investigator": { "id": 24672, "first_name": "Natalie J", "last_name": "Purcell", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1768, "ror": "", "name": "NORTHERN CALIFORNIA INSTITUTE/RES/EDU", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1768, "ror": "", "name": "NORTHERN CALIFORNIA INSTITUTE/RES/EDU", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "We propose a mixed-methods exploratory study to examine moral injury among healthcare workers who have served on the frontlines during the COVID-19 crisis. We aim to assess the prevalence and impact of moral injury related to the COVID-19 crisis, and to identify key risk and protective factors among healthcare workers stationed in high-risk Veterans Affairs (VA) settings. Then, in partnership with VA stakeholders, we will use study findings to design a pragmatic, testable organizational strategy (a “Blueprint”) for moral injury awareness, mitigation, and prevention in healthcare settings. The study will be carried out in three phases: In PHASE 1 (Months 1-9), we will survey healthcare workers (n=300) in VA emergency rooms, inpatient units, and nursing homes. Surveys will assess moral injury, stress, burnout, depression, work climate, and COVID-19-related exposures. We also will gather VA administrative data on COVID hospitalizations/deaths, care quality, and patient/staff satisfaction. We will analyze collected data to identify moral injury risk and protective factors. In PHASE 2 (Months 9-15), we will conduct qualitative interviews (n=30) with workers to gain a more nuanced understanding of moral injury impacts, risks, and protective factors, as well as desired interventions. In PHASE 3 (Months 15-24), we will develop a Blueprint for Moral Injury Awareness, Prevention, & Mitigation in Healthcare Organizations. We will refine it through focus groups with VA stakeholders. The study is designed to address NIOSH’s goals for the Health Care & Social Assistance [62] NORA (National Occupational Research Agenda) Sector, including the Strategic Goals to: “improve workplace safety to reduce traumatic injuries” [6] and “promote safe and healthy work design and well-being” [7], and the Intermediate Goal to “conduct basic/etiologic research to better understand the burden of non-fatal injuries in healthcare and social assistance and associated risk factors” [6.4.1]. This project addresses these goals by examining the prevalence and impact (burden) of moral injury—a trauma-related mental health injury—among healthcare workers, examining individual and organizational risk/protective factors, and producing a Blueprint to help healthcare organizations reduce moral injuries and promote healthcare workers’ wellbeing. This project aligns with the NIOSH Research to Practice (r2p) initiative by: (a) engaging key stakeholders (partnering VA facilities), (b) addressing questions of concern to them, (c) creating a plan to rapidly translate study findings into a product they can pilot, and (d) refining that product through stakeholder engagement. Study outputs will include the Blueprint for Moral Injury Awareness, Prevention, & Mitigation and scholarly publications. Intermediate outcomes will include: (a) improved understanding of the prevalence and impact of moral injury among healthcare workers, (b) identification of risk and protective factors, and (c) dissemination of promising practices for prevention and mitigation. The end outcome—reduced moral injury prevalence and impact among healthcare workers—will be measured in a future R01 implementation-effectiveness trial.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8858", "attributes": { "award_id": "1R03HS028693-01", "title": "Advancing Population and Public health Reporting and Outcomes with Vaccination data Exchange (APPROVE)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24674, "first_name": "Steve", "last_name": "Bernstein", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-30", "end_date": "2022-09-29", "award_amount": 99606, "principal_investigator": { "id": 24675, "first_name": "Sripriya", "last_name": "Rajamani", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 764, "ror": "https://ror.org/017zqws13", "name": "University of Minnesota", "address": "", "city": "", "state": "MN", "zip": "", "country": "United States", "approved": true }, "abstract": "The response to the COVID-19 pandemic in the United States has underscored the need and importance of a robust public health infrastructure. This is occurring in the larger context of increasing reportable infectious diseases over the past decade. Surveillance of reportable infectious diseases (including COVID-19) and corresponding vaccination coverage are coordinated endeavors in public health but known to be complex due to the quagmire of information systems and organizations. Despite advances in technology, many public health HIT systems do not have robust interoperability (seamless electronic data exchange). This study addresses a knowledge-gap by evaluation of interoperability approaches for electronic vaccination data exchange between HIT systems for infectious disease surveillance, vaccinations and electronic health records (EHRs). This interoperability evaluation will be guided by the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) implementation framework. Aim 1 will focus on a novel interoperability tool for electronic vaccination data exchange within the public health realm and characterize the enablers and barriers to its use. Aim 2 will evaluate the use of an evolving interoperability tool for electronic vaccination data exchange across public health and EHRs in clinical care. The study is innovative as it evaluates interoperability tools and approaches across key information systems to facilitate infectious disease surveillance and quality of healthcare. This work is of paramount importance and will be timely as COVID-19 vaccines become available and for understanding effective surveillance strategies for a breadth of vaccine-preventable diseases. The overarching goal of this work is to enhance data-driven decision-making and ultimately healthcare quality by facilitating data exchange between HIT systems within public health and across public health and clinical care. While the study will be done in the State of Minnesota, the research findings are generalizable and applicable to public health settings in other states. The learnings can be utilized for enhancing interoperable electronic data exchanges in clinical care and improving health outcomes.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "8872", "attributes": { "award_id": "1R01FD007476-01", "title": "Nanopore Methods for Determining Capsid Viability", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [ { "id": 24621, "first_name": "Manuel", "last_name": "Osorio", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2021-09-01", "end_date": "2024-08-31", "award_amount": 572610, "principal_investigator": { "id": 24691, "first_name": "Kimberly", "last_name": "Ritola", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 817, "ror": "", "name": "UNIV OF NORTH CAROLINA CHAPEL HILL", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Nanopore Methods for Determining Capsid Viability ABSTRACT AAV (adeno-associated virus) vectors are quickly becoming an important therapeutic tool for treatment of a variety of diseases, resulting in a significant increase in the number of applications to the FDA for approvals for treatment of various diseases. Precise characterization of these AAVs is extremely important for process control and determination of the effectiveness of the final product for both production efficiency and regulatory/quality reasons. We have developed nano-fluidic, synthetic pore-based sensors capable of detecting and quantifying various nanoparticles. These existing sensors can be modified for application to capsid characterization. Demonstrated applications of this technology include DNA and RNA sequencing, SARS-CoV-2 virus detection from saliva (including viral load and infectivity classification) using resistive pulse sensing (RPS), and analysis of ligase detection reaction (LDR) products utilizing Time-of-Flight (TOF) capabilities. Specifically for this project, we will use the nanopore technology to detect capsids and characterize them as either full or empty (Aim 1) and we will extend the sensor capabilities to address high-throughput strategies for inline analysis (Aim 2). Finally, we will implement the sensors into AAV production, validate their responses against established QCAs and use sensor data to optimize production processes (Aim 3). We expect these developments to result in sensor systems that will help to improve AAV production efficiencies, improve final product infectivity, and provide important quality assurance data.", "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1419, "count": 14184 } } }